Home Categories Pharmaceutical intermediates Linagliptin
A5291312

Linagliptin , ≥99% , 668270-12-0

CAS NO.:668270-12-0

Empirical Formula: C25H28N8O2

Molecular Weight: 472.54

MDL number: MFCD14635356

EINECS: 1308068-626-2

Pack Size Price Stock Quantity
10MG RMB23.20 In Stock
50MG RMB31.20 In Stock
100mg RMB39.20 In Stock
250MG RMB64.00 In Stock
1g RMB150.40 In Stock
5g RMB454.40 In Stock
25g RMB2036.80 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 202 ºC
Boiling point: 661.2±65.0 °C(Predicted)
Density  1.39
storage temp.  Refrigerator
solubility  Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly)
pka 10.01±0.20(Predicted)
form  Solid
color  White to Orange
InChIKey LTXREWYXXSTFRX-QGZVFWFLSA-N
SMILES N1(CC#CC)C2=C(N(C)C(=O)N(CC3=NC(C)=C4C(=N3)C=CC=C4)C2=O)N=C1N1CCC[C@@H](N)C1

Description and Uses

Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4. Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign. After optimizing the activity of the initial micromolar lead, two issues that needed to be addressed were activity for hERG and muscarinic receptor M1. Introduction of a butynyl group at the N7 position of the xanthine ring gave much reduced M1 affinity with no measureable hERG activity. Linagliptin inhibits DPP-4 with an IC50=1 nM and is highly selective (>10,000-fold) against DPP-8 and DPP-9. Linagliptin shows no interactions with CYPs up to 50 mM. The described synthesis of linagliptin starts with 8-bromoxanthine, which is alkylated at the N-7 position to introduce the butyne group, followed by alkylation of the N-1 group to introduce the methyl-quinazoline group. Displacement of the bromide with (R)-Boc-3-amino-piperidine followed by deprotection gives linagliptin. When administered to db/db mice orally, linagliptin dose dependently reduced glucose excursion from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition).

dipeptidypeptidase inhibitor, antidiabetic

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H319-H335-H315
Precautionary statements  P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362
HS Code  29335990
Hazardous Substances Data 668270-12-0(Hazardous Substances Data)

RELATED PRODUCTS